DMRA.US Damora Therapeutics, Inc.

Healthcare Biotechnology USA Stocks
21.60 USD
Close of Nov 14, 2026
15.76 38.33
Market cap
USD 1.34B
P/E
12.6x
P/B
3.72x
ROE
-24.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DMRA.US undervalued?

Graham number
Price21.60
Graham value14.94
Premium44.6%

DMRA.US trades 44.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Damora Therapeutics, Inc. fundamental analysis

No fundamental analysis for Damora Therapeutics, Inc. yet.

Damora Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB…

Full company profile